Cargando...
A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials
We propose a robust two-stage design to identify the optimal biological dose for phase I/II clinical trials evaluating both toxicity and efficacy outcomes. In the first stage of dose finding, we use the Bayesian model averaging continual reassessment method to monitor the toxicity outcomes and adopt...
Gardado en:
| Publicado en: | Stat Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5138134/ https://ncbi.nlm.nih.gov/pubmed/27538818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/sim.7082 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|